Ali Behbahani bought $15M of SGP
director, owner at SpyGlass Pharma, Inc.. 937,500 shares at an average of $16.00, traded Feb 9, 2026, filed Feb 11, 2026.
Score components
- +15RoleDirector
- +25Trade size$15.0M at market
- +3Relative to holdingsHoldings up 18%
- 0Price contextNo price history yet
- +15Cluster15 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.6%, 3m -13.5%, 6m -8.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-046676, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | CConversion Common Stockindirect: See Note 2 | +1,619,240 | - | - | 1,619,240 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Common Stockindirect: See Note 2 | +1,370,168 | - | - | 2,989,408 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Common Stockindirect: See Note 2 | +1,370,168 | - | - | 4,359,576 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Common Stockindirect: See Note 2 | +737,962 | - | - | 5,097,538 | Feb 11, 2026 |
| Feb 9, 2026 | POpen-market purchase Common Stockindirect: See Note 2 | +937,500 | $16.00 | $15M | 6,035,038 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Common Stockindirect: See Note 3 | +954,990 | - | - | 954,990 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Common Stockindirect: See Note 3 | +402,273 | - | - | 1,357,263 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Series B Preferred Stockderivativeindirect: See Note 2 | -1,619,240 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Series C-1 Preferred Stockderivativeindirect: See Note 2 | -1,370,168 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Series C-2 Preferred Stockderivativeindirect: See Note 2 | -1,370,168 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Series D Preferred Stockderivativeindirect: See Note 2 | -737,962 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Series A Preferred Stockderivativeindirect: See Note 3 | -954,990 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | CConversion Series B Preferred Stockderivativeindirect: See Note 3 | -402,273 | - | - | 0 | Feb 11, 2026 |
Related signals
Other insiders at SpyGlass Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SpyGlass Pharma, Inc. | Forest Baskett owner | $15M 937,500 shares | +18% | |
| 50Moderate | SpyGlass Pharma, Inc. | Carmen Chang owner | $15M 937,500 shares | +18% | |
| 50Moderate | SpyGlass Pharma, Inc. | Anthony A. Florence Jr. owner | $15M 937,500 shares | +18% | |
| 65Notable | SpyGlass Pharma, Inc. | Bilal Arshad Khan director | $2.2M 135,000 shares | +2477% | |
| 60Notable | SpyGlass Pharma, Inc. | Ra Capital Management, L.p. director, owner | $59M 3,690,000 shares | +146% | |
| 50Moderate | SpyGlass Pharma, Inc. | Mohamad Makhzoumi owner | $15M 937,500 shares | +18% | |
| 50Moderate | SpyGlass Pharma, Inc. | Edward T Mathers owner | $15M 937,500 shares | +18% | |
| 50Moderate | SpyGlass Pharma, Inc. | New Enterprise Associates 17, L.P. owner | $15M 937,500 shares | +18% | |
| 58Moderate | SpyGlass Pharma, Inc. | Geoffrey B Pardo director | $5.0M 312,500 shares | +17% | |
| 50Moderate | SpyGlass Pharma, Inc. | Scott D Sandell owner | $15M 937,500 shares | +18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.